Insulin and C-Peptide Testing: Clinical Purpose
Insulin and C-peptide tests are primarily used to diagnose the cause of hypoglycemia in non-diabetic patients and to distinguish between endogenous hyperinsulinism (such as insulinoma) and exogenous insulin administration or other causes of low blood sugar. 1
Primary Clinical Applications
1. Evaluation of Hypoglycemia in Non-Diabetic Patients
The Endocrine Society guidelines establish that when evaluating unexplained hypoglycemia in seemingly well individuals, you should measure plasma glucose, insulin, C-peptide, proinsulin, and β-hydroxybutyrate during a hypoglycemic episode 1. The key diagnostic thresholds during hypoglycemia (glucose <55 mg/dL or 3.0 mmol/L) are:
- Insulin ≥3.0 µU/mL (18 pmol/L)
- C-peptide ≥0.6 ng/mL (0.2 nmol/L)
- Proinsulin ≥5.0 pmol/L
These elevated levels during hypoglycemia indicate endogenous hyperinsulinism (such as insulinoma or nesidioblastosis) 1.
Conversely, during normal physiology when glucose drops below 55 mg/dL, insulin secretion should be virtually completely suppressed, with insulin <3 µU/mL and C-peptide <0.6 ng/mL 1. Finding inappropriately elevated levels indicates pathologic insulin secretion.
2. Distinguishing Endogenous vs. Exogenous Insulin
C-peptide is the critical differentiator between endogenous and exogenous insulin:
- High insulin + High C-peptide = Endogenous insulin production (insulinoma, sulfonylurea use, insulin autoimmune syndrome)
- High insulin + Low/undetectable C-peptide = Exogenous insulin administration (factitious hypoglycemia)
This distinction is crucial because C-peptide is co-secreted with insulin in a 1:1 ratio by pancreatic beta cells but is NOT present in pharmaceutical insulin preparations 2, 3.
3. Diabetes Classification and Management
In patients with diabetes, C-peptide measurement helps classify diabetes type and guide treatment decisions 4, 2:
- C-peptide <0.2 nmol/L suggests Type 1 diabetes with absolute insulin deficiency 5
- C-peptide >0.6 nmol/L indicates Type 2 diabetes or MODY with preserved beta-cell function 5
The utility is greatest 3-5 years after diagnosis when persistent C-peptide suggests Type 2 or monogenic diabetes rather than Type 1, potentially avoiding unnecessary insulin therapy 2, 6.
4. Additional Clinical Uses
C-peptide measurement assists in:
- Identifying insulin autoimmune hypoglycemia (very high insulin levels with high C-peptide and positive insulin antibodies) 1, 7
- Evaluating post-gastric bypass hypoglycemia (nesidioblastosis) 1
- Screening for surreptitious sulfonylurea use (high insulin and C-peptide with detectable oral agents) 1
- Predicting remission in Type 1 diabetes 6
- Patient selection for islet cell transplantation 6
Testing Strategy
When spontaneous hypoglycemia cannot be observed, provoke it through:
- 72-hour supervised fast for suspected fasting hypoglycemia 1
- Mixed meal test for suspected postprandial hypoglycemia 7
During the provoked episode, measure the complete panel: glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, and screen for oral hypoglycemic agents 1.
Critical Pitfalls
Important caveats to avoid misinterpretation:
- Insulin/glucose ratios have no diagnostic utility 1
- Renal insufficiency can elevate C-peptide levels independently 1
- C-peptide assays lack standardization—significant variability exists between laboratories, limiting the reliability of specific cut-off values 5
- In Type 2 diabetes, insulin resistance confounds C-peptide interpretation, limiting its clinical utility 4, 8
- C-peptide has a longer half-life than insulin, making it more stable for measurement but less reflective of acute insulin secretion 2, 3
The bottom line: These tests are essential diagnostic tools for investigating hypoglycemia in non-diabetic patients, with C-peptide serving as the key marker to differentiate endogenous insulin production from exogenous sources or non-insulin-mediated hypoglycemia.